Somatic gene therapy for dyslipidemias

Ligia Belalcazar, Lawrence Chan

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Somatic gene transfer is a valuable tool for the in vivo evaluation of lipoprotein metabolism. It has been used to dissect metabolic pathways, to establish structure-function relationships of various gene products, and to evaluate conventional lipid-lowering and novel therapeutic genes for the treatment of lipoprotein disorders. In this article we review some general aspects of somatic gene therapy and the different vehicles used for the delivery of therapeutic genes. We highlight some recent advances in adenoviral vector development that make this vector an attractive system for clinical trials.

Original languageEnglish (US)
Pages (from-to)194-214
Number of pages21
JournalJournal of Laboratory and Clinical Medicine
Volume134
Issue number3
DOIs
StatePublished - 1999
Externally publishedYes

Fingerprint

Gene therapy
Dyslipidemias
Genetic Therapy
Genes
Lipoproteins
Gene transfer
Metabolism
Metabolic Networks and Pathways
Lipids
Therapeutics
Clinical Trials

ASJC Scopus subject areas

  • Medicine(all)
  • Pathology and Forensic Medicine

Cite this

Somatic gene therapy for dyslipidemias. / Belalcazar, Ligia; Chan, Lawrence.

In: Journal of Laboratory and Clinical Medicine, Vol. 134, No. 3, 1999, p. 194-214.

Research output: Contribution to journalArticle

@article{8518fb92a9ea4b17b3c13f665a301419,
title = "Somatic gene therapy for dyslipidemias",
abstract = "Somatic gene transfer is a valuable tool for the in vivo evaluation of lipoprotein metabolism. It has been used to dissect metabolic pathways, to establish structure-function relationships of various gene products, and to evaluate conventional lipid-lowering and novel therapeutic genes for the treatment of lipoprotein disorders. In this article we review some general aspects of somatic gene therapy and the different vehicles used for the delivery of therapeutic genes. We highlight some recent advances in adenoviral vector development that make this vector an attractive system for clinical trials.",
author = "Ligia Belalcazar and Lawrence Chan",
year = "1999",
doi = "10.1016/S0022-2143(99)90199-3",
language = "English (US)",
volume = "134",
pages = "194--214",
journal = "Translational Research",
issn = "1931-5244",
publisher = "Mosby Inc.",
number = "3",

}

TY - JOUR

T1 - Somatic gene therapy for dyslipidemias

AU - Belalcazar, Ligia

AU - Chan, Lawrence

PY - 1999

Y1 - 1999

N2 - Somatic gene transfer is a valuable tool for the in vivo evaluation of lipoprotein metabolism. It has been used to dissect metabolic pathways, to establish structure-function relationships of various gene products, and to evaluate conventional lipid-lowering and novel therapeutic genes for the treatment of lipoprotein disorders. In this article we review some general aspects of somatic gene therapy and the different vehicles used for the delivery of therapeutic genes. We highlight some recent advances in adenoviral vector development that make this vector an attractive system for clinical trials.

AB - Somatic gene transfer is a valuable tool for the in vivo evaluation of lipoprotein metabolism. It has been used to dissect metabolic pathways, to establish structure-function relationships of various gene products, and to evaluate conventional lipid-lowering and novel therapeutic genes for the treatment of lipoprotein disorders. In this article we review some general aspects of somatic gene therapy and the different vehicles used for the delivery of therapeutic genes. We highlight some recent advances in adenoviral vector development that make this vector an attractive system for clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=0033198804&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033198804&partnerID=8YFLogxK

U2 - 10.1016/S0022-2143(99)90199-3

DO - 10.1016/S0022-2143(99)90199-3

M3 - Article

VL - 134

SP - 194

EP - 214

JO - Translational Research

JF - Translational Research

SN - 1931-5244

IS - 3

ER -